Journal
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Volume 26, Issue 3, Pages 94-100Publisher
WILEY-BLACKWELL
DOI: 10.1002/jbt.20414
Keywords
Mycalamide; Efflux; PDR; Resistance
Categories
Funding
- Victoria University of Wellington
- New Zealand Agency for International Development
Ask authors/readers for more resources
The mycalamides belong to a family of protein synthesis inhibitors noted for antifungal, antitumour, antiviral, immunosuppressive, and nematocidal activities. Here we report a systematic analysis of the role of drug efflux pumps in mycalamide resistance and the first isolation of mycalamide E. In human cell lines, neither P-glycoprotein overexpression nor the use of efflux pump inhibitors significantly modulated mycalamide A toxicity in the systems tested. In Saccharomyces cerevisiae, it appears that mycalamide A is subject to efflux by the principle mediator of xenobiotic efflux, Pdr5p along with the major facilitator superfamily pump Tpo1p. Mycalamide E showed a similar efflux profile. These results suggest that future drugs based on the mycalamides are likely to be valuable in situations where efflux pump-based resistance leads to failure of other chemotherapeutic approaches, although efflux may be a mediator of resistance in antifungal applications. (c) 2012 Wiley Periodicals, Inc. J Biochem Mol Toxicol 26:94-100, 2012; View this article online at wileyonlinelibrary.com. DOI 10:1002/jbt.20414
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available